The 8 most recent market catalysts affecting $AGIO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 55
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50
B of A Securities analyst Alec Stranahan maintained a 'Buy' rating on Agios Pharmaceuticals (AGIO) and raised the price target from $46 to $50. This analyst action signals continue…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52
Citigroup analyst Samantha Semenkow maintained a 'Buy' rating on Agios Pharmaceuticals (AGIO) and raised the price target from $46 to $52. This action signals increased confidence …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55
HC Wainwright & Co. analyst Emily Bodnar has maintained a 'Buy' rating for Agios Pharmaceuticals and raised the price target from $52 to $55. This action signals continued confiden…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Agios Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.
The mixed Q2 results for Agios Pharmaceuticals (AGIO) are a significant corporate catalyst, directly impacting its share price negatively. Investors are likely reacting to either l…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate
Agios Pharmaceuticals' Q2 earnings report shows a mixed but generally positive picture. The company's sales of $44.745 million significantly surpassed analyst expectations of $25.5…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 85
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Agios Pharmaceuticals announced the discontinuation of its tebapivat program for sickle cell disease following Phase 2 trial results. While the drug showed some improvements in hem…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 92
Agios Pharmaceutical shares are trading lower after the company announced topline results from its Phase 2 trial of tebapivat. Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease.
The negative Phase 2 trial results for tebapivat are a major corporate catalyst for Agios Pharmaceuticals, directly impacting its stock price. The failure to establish a differenti…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 65
Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease
Agios Pharmaceuticals has decided to discontinue the development of tebapivat for sickle cell disease following Phase 2 trial results. While the drug showed some efficacy in improv…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.